Design of a biodegradable bone cement with enhanced mechanical and raloxifene-delivering properties
Abstract
Bone metastases associated with breast cancer weaken bone tissue and increase fracture risk, creating a need for injectable biomaterials that combine defect filling, fracture resistance and localized therapeutic activity. In this study, we developed a multifunctional magnesium-calcium phosphate cement (MgCPC) reinforced with electrospun polycaprolactone/polyethylene glycol (PCL/PEG) fibers loaded with raloxifene hydrochloride (RLX), a selective estrogen-receptor modulator with both anti-estrogenic activity in breast tissue and beneficial effects on bone. To our knowledge, this is the first study to incorporate RLX-loaded electrospun fibers into an injectable MgCPC matrix to simultaneously provide fiber-mediated toughening and delivery of biologically active RLX. Bead-free PCL/PEG fibers were produced by electrospinning, cryogenically milled and incorporated into the cement at 2 wt%. Fiber incorporation preserved cement injectability, with values of 91.3 ± 2.0% for MgCPC and 92.4 ± 2.0% for RLX-loaded fiber-reinforced MgCPC. The final setting time increased from 7.9 ± 0.4-11.2 ± 0.9 min but remained compatible with injectable handling. X-ray diffraction and Rietveld refinement showed similar crystalline phase proportions among the samples, indicating that fiber incorporation did not substantially alter the final phase composition. Although the addition of fibers reduced compressive strength from 32.6 ± 3.8-10.1 ± 1.1 MPa, it markedly enhanced fracture resistance. The work of fracture increased from 110.8 ± 22.4 J.m -2 for MgCPC to 416.1 ± 82.9 J⋅m -2 for the RLX-loaded composite, corresponding to an approximately 3.8-fold improvement. All tested cements were cytocompatible with human hFOB osteoblasts. In addition, cement extracts from the RLX-loaded cement significantly inhibited estrogen-responsive MCF-7 breast cancer cell proliferation, confirming the release of biologically active RLX. Fiber incorporation also slowed cement degradation in vivo, with 79.3% of the RLX-loaded composite remaining after 42 days compared with 51.6% for MgCPC. These findings demonstrate the potential of RLX-loaded fiber-reinforced MgCPC as an injectable multifunctional biomaterial combining preserved handling properties, enhanced fracture toughness, cytocompatibility, biological activity against estrogen-responsive MCF-7 cells and modulated degradation for future application in bone lesions associated with hormone-responsive breast cancer.
Related
- Effects of Mepiquat Chloride Application Timing and Concentration on Soybean Plant Architecture and Stem Mechanical Properties
- Associations of age, sex, and bicuspid aortic valve with biaxial mechanical properties and circumferential residual stress in ascending thoracic aortic aneurysm
- Mechanical properties of gummies are associated with threat-related behavior and neuroglial markers in mice
- Variation and adaptation in the mechanical properties of primate molar tooth enamel
- Microstructure determines the difference between the mechanical properties of melanized and non‐melanized domestic pigeon feathers
BibTeX
@article{delnatte2026design,
title = {{Design of a biodegradable bone cement with enhanced mechanical and raloxifene-delivering properties}},
author = {Alexia Delnatte and Orlane Jouanneau and Tia Maria Howayek and Marilyn Kajdan and Fanny Salmeron and Pierre-Yves Collart-Dutilleul and Vincent Cavaillès and Mikhael Bechelany},
journal = {Materials Today Communications},
year = {2026},
month = oct,
doi = {10.1016/j.mtcomm.2026.115905},
url = {https://hal.science/hal-05775918v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Design of a biodegradable bone cement with enhanced mechanical and raloxifene-delivering properties
AU - Alexia Delnatte
AU - Orlane Jouanneau
AU - Tia Maria Howayek
AU - Marilyn Kajdan
AU - Fanny Salmeron
AU - Pierre-Yves Collart-Dutilleul
AU - Vincent Cavaillès
AU - Mikhael Bechelany
PY - 2026
DA - 2026/10/02
JO - Materials Today Communications
DO - 10.1016/j.mtcomm.2026.115905
UR - https://hal.science/hal-05775918v1
AB - Bone metastases associated with breast cancer weaken bone tissue and increase fracture risk, creating a need for injectable biomaterials that combine defect filling, fracture resistance and localized therapeutic activity. In this study, we developed a multifunctional magnesium-calcium phosphate cement (MgCPC) reinforced with electrospun polycaprolactone/polyethylene glycol (PCL/PEG) fibers loaded with raloxifene hydrochloride (RLX), a selective estrogen-receptor modulator with both anti-estrogenic activity in breast tissue and beneficial effects on bone. To our knowledge, this is the first study to incorporate RLX-loaded electrospun fibers into an injectable MgCPC matrix to simultaneously provide fiber-mediated toughening and delivery of biologically active RLX. Bead-free PCL/PEG fibers were produced by electrospinning, cryogenically milled and incorporated into the cement at 2 wt%. Fiber incorporation preserved cement injectability, with values of 91.3 ± 2.0% for MgCPC and 92.4 ± 2.0% for RLX-loaded fiber-reinforced MgCPC. The final setting time increased from 7.9 ± 0.4-11.2 ± 0.9 min but remained compatible with injectable handling. X-ray diffraction and Rietveld refinement showed similar crystalline phase proportions among the samples, indicating that fiber incorporation did not substantially alter the final phase composition. Although the addition of fibers reduced compressive strength from 32.6 ± 3.8-10.1 ± 1.1 MPa, it markedly enhanced fracture resistance. The work of fracture increased from 110.8 ± 22.4 J.m -2 for MgCPC to 416.1 ± 82.9 J⋅m -2 for the RLX-loaded composite, corresponding to an approximately 3.8-fold improvement. All tested cements were cytocompatible with human hFOB osteoblasts. In addition, cement extracts from the RLX-loaded cement significantly inhibited estrogen-responsive MCF-7 breast cancer cell proliferation, confirming the release of biologically active RLX. Fiber incorporation also slowed cement degradation in vivo, with 79.3% of the RLX-loaded composite remaining after 42 days compared with 51.6% for MgCPC. These findings demonstrate the potential of RLX-loaded fiber-reinforced MgCPC as an injectable multifunctional biomaterial combining preserved handling properties, enhanced fracture toughness, cytocompatibility, biological activity against estrogen-responsive MCF-7 cells and modulated degradation for future application in bone lesions associated with hormone-responsive breast cancer.
SN - 2352-4928
ER -